S&P 500   4,401.76 (+1.19%)
DOW   34,637.65 (+1.37%)
QQQ   348.70 (+1.20%)
AAPL   162.97 (+2.05%)
MSFT   305.87 (+3.09%)
FB   300.89 (+2.12%)
GOOGL   2,640.01 (+2.14%)
AMZN   2,861.86 (+3.04%)
TSLA   872.59 (-6.91%)
NVDA   225.10 (-1.15%)
BABA   113.87 (+0.44%)
NIO   22.01 (-2.87%)
AMD   106.82 (-3.51%)
CGC   7.03 (-2.77%)
MU   81.28 (-0.84%)
GE   90.29 (+1.09%)
T   24.31 (+0.25%)
F   19.97 (+0.30%)
DIS   137.50 (+2.92%)
AMC   15.21 (-4.58%)
PFE   54.49 (+2.79%)
ACB   3.93 (-3.20%)
BA   194.43 (+0.08%)
S&P 500   4,401.76 (+1.19%)
DOW   34,637.65 (+1.37%)
QQQ   348.70 (+1.20%)
AAPL   162.97 (+2.05%)
MSFT   305.87 (+3.09%)
FB   300.89 (+2.12%)
GOOGL   2,640.01 (+2.14%)
AMZN   2,861.86 (+3.04%)
TSLA   872.59 (-6.91%)
NVDA   225.10 (-1.15%)
BABA   113.87 (+0.44%)
NIO   22.01 (-2.87%)
AMD   106.82 (-3.51%)
CGC   7.03 (-2.77%)
MU   81.28 (-0.84%)
GE   90.29 (+1.09%)
T   24.31 (+0.25%)
F   19.97 (+0.30%)
DIS   137.50 (+2.92%)
AMC   15.21 (-4.58%)
PFE   54.49 (+2.79%)
ACB   3.93 (-3.20%)
BA   194.43 (+0.08%)
S&P 500   4,401.76 (+1.19%)
DOW   34,637.65 (+1.37%)
QQQ   348.70 (+1.20%)
AAPL   162.97 (+2.05%)
MSFT   305.87 (+3.09%)
FB   300.89 (+2.12%)
GOOGL   2,640.01 (+2.14%)
AMZN   2,861.86 (+3.04%)
TSLA   872.59 (-6.91%)
NVDA   225.10 (-1.15%)
BABA   113.87 (+0.44%)
NIO   22.01 (-2.87%)
AMD   106.82 (-3.51%)
CGC   7.03 (-2.77%)
MU   81.28 (-0.84%)
GE   90.29 (+1.09%)
T   24.31 (+0.25%)
F   19.97 (+0.30%)
DIS   137.50 (+2.92%)
AMC   15.21 (-4.58%)
PFE   54.49 (+2.79%)
ACB   3.93 (-3.20%)
BA   194.43 (+0.08%)
S&P 500   4,401.76 (+1.19%)
DOW   34,637.65 (+1.37%)
QQQ   348.70 (+1.20%)
AAPL   162.97 (+2.05%)
MSFT   305.87 (+3.09%)
FB   300.89 (+2.12%)
GOOGL   2,640.01 (+2.14%)
AMZN   2,861.86 (+3.04%)
TSLA   872.59 (-6.91%)
NVDA   225.10 (-1.15%)
BABA   113.87 (+0.44%)
NIO   22.01 (-2.87%)
AMD   106.82 (-3.51%)
CGC   7.03 (-2.77%)
MU   81.28 (-0.84%)
GE   90.29 (+1.09%)
T   24.31 (+0.25%)
F   19.97 (+0.30%)
DIS   137.50 (+2.92%)
AMC   15.21 (-4.58%)
PFE   54.49 (+2.79%)
ACB   3.93 (-3.20%)
BA   194.43 (+0.08%)
NASDAQ:AGLE

Aeglea BioTherapeutics Stock Forecast, Price & News

$4.07
-0.13 (-3.10%)
(As of 01/27/2022 11:40 AM ET)
Add
Compare
Today's Range
$4.04
$4.20
50-Day Range
$3.50
$6.68
52-Week Range
$3.47
$8.79
Volume
1,633 shs
Average Volume
310,278 shs
Market Capitalization
$200.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.44
30 days | 90 days | 365 days | Advanced Chart
Receive AGLE News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeglea BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.


Aeglea BioTherapeutics logo

About Aeglea BioTherapeutics

Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.

Headlines

Why Aeglea BioTherapeutics Stock Is Way Down Today
December 6, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AGLE
Employees
90
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$2.92 per share

Profitability

Net Income
$-80.89 million
Pretax Margin
-450.16%

Debt

Price-To-Earnings

Miscellaneous

Free Float
47,446,000
Market Cap
$200.73 million
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
1/27/2022
Next Earnings (Estimated)
3/17/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.30 out of 5 stars

Medical Sector

292nd out of 1,420 stocks

Pharmaceutical Preparations Industry

125th out of 684 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












Aeglea BioTherapeutics (NASDAQ:AGLE) Frequently Asked Questions

Is Aeglea BioTherapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aeglea BioTherapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aeglea BioTherapeutics stock.
View analyst ratings for Aeglea BioTherapeutics
or view top-rated stocks.

How has Aeglea BioTherapeutics' stock price been impacted by Coronavirus (COVID-19)?

Aeglea BioTherapeutics' stock was trading at $5.38 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AGLE shares have decreased by 24.3% and is now trading at $4.07.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Aeglea BioTherapeutics?

Aeglea BioTherapeutics saw a increase in short interest in December. As of December 15th, there was short interest totaling 937,400 shares, an increase of 36.5% from the November 30th total of 686,500 shares. Based on an average daily trading volume, of 278,400 shares, the short-interest ratio is currently 3.4 days. Approximately 2.3% of the company's stock are sold short.
View Aeglea BioTherapeutics' Short Interest
.

When is Aeglea BioTherapeutics' next earnings date?

Aeglea BioTherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for Aeglea BioTherapeutics
.

How were Aeglea BioTherapeutics' earnings last quarter?

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) released its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.03. The biotechnology company earned $1.40 million during the quarter, compared to the consensus estimate of $1.38 million.
View Aeglea BioTherapeutics' earnings history
.

What price target have analysts set for AGLE?

4 brokers have issued twelve-month target prices for Aeglea BioTherapeutics' shares. Their forecasts range from $9.00 to $20.00. On average, they expect Aeglea BioTherapeutics' stock price to reach $13.67 in the next twelve months. This suggests a possible upside of 235.8% from the stock's current price.
View analysts' price targets for Aeglea BioTherapeutics
or view top-rated stocks among Wall Street analysts.

Who are Aeglea BioTherapeutics' key executives?

Aeglea BioTherapeutics' management team includes the following people:
  • Anthony G. Quinn, President, Chief Executive Officer & Director
  • Leslie Sloan, Chief Operating Officer
  • Jonathan D. Alspaugh, Chief Financial Officer (LinkedIn Profile)
  • Steven Weber, Chief Accounting Officer, VP & Controller
  • Scott W. Rowlinson, Vice President-Research

What is Anthony Quinn's approval rating as Aeglea BioTherapeutics' CEO?

3 employees have rated Aeglea BioTherapeutics CEO Anthony Quinn on Glassdoor.com. Anthony Quinn has an approval rating of 100% among Aeglea BioTherapeutics' employees. This puts Anthony Quinn in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Aeglea BioTherapeutics own?

When did Aeglea BioTherapeutics IPO?

(AGLE) raised $60 million in an IPO on Thursday, April 7th 2016. The company issued 3,500,000 shares at a price of $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Needham & Company was co-manager.

What is Aeglea BioTherapeutics' stock symbol?

Aeglea BioTherapeutics trades on the NASDAQ under the ticker symbol "AGLE."

Who are Aeglea BioTherapeutics' major shareholders?

Aeglea BioTherapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Pinnacle Wealth Planning Services Inc. (0.02%). Company insiders that own Aeglea BioTherapeutics stock include Anthony G Quinn, Armen Shanafelt and Jonathan Alspaugh.
View institutional ownership trends for Aeglea BioTherapeutics
.

Which institutional investors are buying Aeglea BioTherapeutics stock?

AGLE stock was bought by a variety of institutional investors in the last quarter, including Pinnacle Wealth Planning Services Inc.. Company insiders that have bought Aeglea BioTherapeutics stock in the last two years include Anthony G Quinn, Armen Shanafelt, and Jonathan Alspaugh.
View insider buying and selling activity for Aeglea BioTherapeutics
or or view top insider-buying stocks.

How do I buy shares of Aeglea BioTherapeutics?

Shares of AGLE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aeglea BioTherapeutics' stock price today?

One share of AGLE stock can currently be purchased for approximately $4.07.

How much money does Aeglea BioTherapeutics make?

Aeglea BioTherapeutics has a market capitalization of $200.73 million. The biotechnology company earns $-80.89 million in net income (profit) each year or ($1.03) on an earnings per share basis.

How many employees does Aeglea BioTherapeutics have?

Aeglea BioTherapeutics employs 90 workers across the globe.

What is Aeglea BioTherapeutics' official website?

The official website for Aeglea BioTherapeutics is www.aegleabio.com.

Where are Aeglea BioTherapeutics' headquarters?

Aeglea BioTherapeutics is headquartered at 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746.

How can I contact Aeglea BioTherapeutics?

Aeglea BioTherapeutics' mailing address is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. The biotechnology company can be reached via phone at (512) 942-2935, via email at [email protected], or via fax at 512-872-5121.


This page was last updated on 1/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.